Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840
Debt
Debt-to-Equity Ratio0.35
Current Ratio4.11
Quick Ratio4.11
Price-To-Earnings
Trailing P/E Ratio-1.18
Forward P/E Ratio-2.13
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.75 million
Price / Sales27.68
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book2.55
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-138.85%
Return on Assets-75.78%
Miscellaneous
Employees51
Outstanding Shares72,580,000
Market Cap$107.42
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) issued its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.05. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
5 equities research analysts have issued twelve-month price objectives for Trevena's stock. Their predictions range from $2.50 to $10.00. On average, they expect Trevena's share price to reach $6.30 in the next twelve months. This suggests a possible upside of 340.6% from the stock's current price. View Analyst Ratings for Trevena.
What is the consensus analysts' recommendation for Trevena?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Trevena?
Trevena saw a decline in short interest in June. As of June 29th, there was short interest totalling 5,544,352 shares, a decline of 28.0% from the June 15th total of 7,698,995 shares. Based on an average trading volume of 1,744,518 shares, the short-interest ratio is currently 3.2 days. Currently, 9.8% of the company's shares are short sold. View Trevena's Current Options Chain.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Evelo Biosciences (EVLO), Achillion Pharmaceuticals (ACHN), Syros Pharmaceuticals (SYRS), American Brivision (Holding) (ABVC), ProMetic Life Sciences (PFSCF), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Savara (SVRA), Ra Pharmaceuticals (RARX), MediciNova (MNOV), Xeris Pharmaceuticals (XERS), Mersana Therapeutics (MRSN), Bellicum Pharmaceuticals (BLCM), Clementia Pharmaceuticals (CMTA) and Clearside Biomedical (CLSD).
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Dr. Maxine Gowen, CEO, Pres & Exec. Director (Age 60)
- Ms. Carrie L. Bourdow, Exec. VP & COO (Age 55)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Dr. Jonathan Violin Ph.D., Sr. VP of Scientific Affairs & Investor Relations Officer (Age 43)
- Mr. John M. Limongelli, Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
Has Trevena been receiving favorable news coverage?
News stories about TRVN stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trevena earned a media sentiment score of 0.09 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $1.43.
How big of a company is Trevena?
Trevena has a market capitalization of $107.42 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 200, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (NASDAQ TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
